Literature DB >> 10738107

Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner.

M P Jones1, M A Melan, P A Witt-Enderby.   

Abstract

There are conflicting claims for the role of melatonin in oncogenesis. In addition, the mechanism(s) underlying melatonin's effects in oncogenic processes is (are) unknown. In this study, the effects of melatonin exposure on cell proliferation and transformation were assessed in NIH3T3 cells transfected with either the human mt(1) (NIH-mt1) or MT(2) (NIH-MT2) melatonin receptors. The effects of melatonin exposure on proliferation was assessed by direct cell counts and [(3)H]thymidine uptake assays. The effect of chronic melatonin pretreatment on transformation was assessed by focus assays. In both NIH-mt1 and NIH-MT2 cells, melatonin pretreatment decreased cell proliferation and transformation. Control (NIH-neo) cells did not show this effect. However, as revealed by the [(3)H]thymidine uptake assays, an increase in DNA synthesis occurred in NIH-mt1 cells, whereas no increase occurred in the NIH-MT2 or NIH-neo cells. Upon examination of melatonin receptors, a decrease in the function of both mt(1) and MT(2) receptors occurred. These data suggest that perhaps an attenuation of receptor-mediated processes are involved in the anti-proliferative and anti-transformation capabilities of melatonin in NIH3T3 cells. In addition, based on the [(3)H]thymidine assays, receptor mediated signal transduction mechanisms may slow the growth of cells via actions on the cell cycle. The results from this study shed new insight on the putative mechanisms underlying melatonin's effects on cell proliferation and transformation and lends support for a protective role of melatonin in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738107     DOI: 10.1016/s0304-3835(99)00394-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

2.  Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development.

Authors:  Feng-Yan Lin; Chiao-Wen Lin; Shun-Fa Yang; Wei-Jiunn Lee; Yung-Wei Lin; Liang-Ming Lee; Junn-Liang Chang; Wei-Chun Weng; Chien-Huang Lin; Ming-Hsien Chien
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

3.  Inhibition of iron overload-induced apoptosis and necrosis of bone marrow mesenchymal stem cells by melatonin.

Authors:  Fan Yang; Yuan Li; Gege Yan; Tianyi Liu; Chao Feng; Rui Gong; Ye Yuan; Fengzhi Ding; Lai Zhang; Elina Idiiatullina; Valentin Pavlov; Zhenbo Han; Wenya Ma; Qi Huang; Ying Yu; Zhengyi Bao; Xiuxiu Wang; Bingjie Hua; Zhimin Du; Benzhi Cai; Lei Yang
Journal:  Oncotarget       Date:  2017-05-09

4.  Storage Temperature Alters the Expression of Differentiation-Related Genes in Cultured Oral Keratinocytes.

Authors:  Tor Paaske Utheim; Rakibul Islam; Ida G Fostad; Jon R Eidet; Amer Sehic; Ole K Olstad; Darlene A Dartt; Edward B Messelt; May Griffith; Lara Pasovic
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

5.  Genetic Variations of Melatonin Receptor Type 1A are Associated with the Clinicopathologic Development of Urothelial Cell Carcinoma.

Authors:  Yung-Wei Lin; Shian-Shiang Wang; Yu-Ching Wen; Min-Che Tung; Liang-Ming Lee; Shun-Fa Yang; Ming-Hsien Chien
Journal:  Int J Med Sci       Date:  2017-09-04       Impact factor: 3.738

Review 6.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.